Capacity development to facilitate access to fexinidazole
Objective: Support fexinidazole access for gambiense sleeping sickness patients through capacity strengthening activities at national and local levels of the health system in line with the WHO treatment guidelines.
Project start: 2020
The project, known as FEX-g-HAT, is facilitating the delivery and uptake of fexinidazole, the first all-oral treatment for sleeping sickness, into selected African endemic countries through strengthened health care capacity and coordination via: the HAT Platform, a clinical research, training and access-supporting network of over 120 institutions; through trainings in the use of new tools; and reinforced pharmacovigilance channels for introduction of the new treatment.
The FEX-g-HAT project brings together a consortium of experts: DNDi, the National Control Programmes for Human African Trypanosomiasis of the Democratic Republic of Congo and Guinea, the Research Institute for Development (IRD), and the Institute of Tropical Medicine Antwerp.
How clinical research can contribute to strengthening health systems in low resource countries. Tropical Medicines and Infectious Diseases, 2020
by Mbo F, Mutombo W, Ngolo D, Kabangu P, Valverde Mordt O, Strub-Wourgaft N, Mwamba E.
This project is part of the EDCTP2 programme, which is supported by the European Union.
Get our latest news, personal stories, research articles, and job opportunities.